Table 1.
Characteristics of patients (n = 17) included in the final analysis and pretransplant and posttransplant details of their allogeneic hematopoietic stem cell transplantation (HSCT).
| Characteristics of HSCT recipients | Total number | % |
|---|---|---|
| Underlying disease | ||
| Acute myeloid leukemia (AML) | 12 | 70.6 |
| Acute lymphoblastic leukemia | 2 | 11.8 |
| Lymphoma | 2 | 11.8 |
| Aplastic anemia | 1 | 5.9 |
| Conditioning regimen | ||
| Myeloablative | 8 | 47.1 |
| Reduced intensity | 9 | 52.9 |
| Graft | ||
| Peripheral blood stem cells | 16 | 94.1 |
| Bone marrow | 1 | 5.9 |
| Donor | ||
| Related donor | 9 | 52.9 |
| Unrelated donor | 8 | 47.1 |
| HLA match | ||
| Match | 16 | 94.1 |
| Mismatch | 1 | 5.9 |
| EBMT score32 | ||
| Score ≤2 (low risk) | 6 | 35.3 |
| Score >2 (high risk) | 11 | 64.7 |
| Previous HSCT | ||
| First HSCT | 14 | 82.4 |
| Previous allogeneic HSCT | 1 | 5.9 |
| Previous autologous HSCT | 2 | 11.8 |
| Immunosuppressiona | ||
| No immunosuppressive therapy | 6 | 35.3 |
| Immunosuppressive therapyb | 11 | 64.7 |
| Corticosteroids | 4 | 23.5 |
| Cyclosporine | 7 | 41.2 |
| Tacrolimus | 1 | 5.9 |
| Sirolimus | 1 | 5.9 |
| Severity of prior acute GvHD | ||
| None | 13 | 76.5 |
| I–II | 3 | 17.6 |
| III–IV | 1 | 5.9 |
| Chronic GvHD | ||
| None | 5 | 29.4 |
| I–II (mild to moderate) | 12 | 70.6 |
| III–IV (severe) | 0 | 0 |
| Affected organsb | ||
| Skin | 4 | 23.5 |
| Mucosa | 4 | 23.5 |
| Liver | 9 | 52.9 |
| Eyes | 2 | 11.8 |
| Comorbidities prior vaccination | ||
| Cardiovascular disease | 4 | 23.5 |
| Diabetes mellitus | 2 | 11.8 |
| Thrombosis or embolism | 3 | 17.6 |
aImmunosuppressive therapy at the time of first vaccination.
bMore than one possible.
EBMT European Society of Blood and Marrow Transplantation, GvHD graft-versus-host disease, HLA human leukocyte antigen.